Year: 2019

CAMBRIDGE, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today reported third quarter 2019 financial results and provided an overview of operational progress.“Over the last quarter, our team has successfully manufactured RTX-134 for our Phase 1b trial for the treatment of patients with phenylketonuria. Our clinical sites are actively recruiting patients, and we plan to announce when we have treated the first patient. In order for us to share follow up data from the first patients treated in the study, we expect to report initial clinical results during the first quarter of 2020,” said Pablo J. Cagnoni, M.D., chief executive officer of Rubius Therapeutics....

ST. LOUIS, Nov. 14, 2019 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today reported financial results for the third quarter ended September 30, 2019.“The third quarter was highlighted by successful reengagement with the capital markets, meaningful progress in our commercial growth strategy, and continued innovation and industry collaboration,” said David Fischel, Chairman and CEO. “We are pleased with the methodical progress across all aspects of Stereotaxis.”“In the quarter, we listed on the NYSE American exchange and closed a $25 million equity financing. These reflect increasing awareness and confidence in Stereotaxis’ significant clinical value and growth opportunity. Stereotaxis is in the strongest financial position in its history,...

STUDIO CITY, CA, Nov. 14, 2019 (GLOBE NEWSWIRE) — Tix Corporation (the “Company”) (OTCQX: TIXC), a leading provider of discount ticketing services, today reported results for the third quarter and first nine months ended September 30, 2019.   Third Quarter 2019 Business Highlights:REVENUE – Revenue declined 6% over the prior year period.   ADJUSTED EARNINGS – Adjusted Earnings, as defined below, and adjusted for non-routine legal and advisory services for corporate and governance matters, declined slightly to $91,000 as compared to $103,000 in the prior year period.   First Nine Months 2019 Business Highlights:REVENUE GROWTH – Revenue improved 2% over the prior year period.   ADJUSTED EARNINGS – Adjusted Earnings, as defined below, and which includes an adjustment for non-routine legal and advisory services for corporate and...

Received Written End-of-Phase 1 Meeting Minutes Outlining Clear Development Path for PB2452Completed Phase 2a Trial of PB2452 in Older and Elderly Subjects on Dual Antiplatelet TherapyInitiated Registrational Phase 2b Trial of PB2452 in Older and Elderly Subjects on Dual Antiplatelet TherapyMALVERN, Pa. and SAN DIEGO, Nov. 14, 2019 (GLOBE NEWSWIRE) — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today reported financial results for the third quarter ended September 30, 2019 and provided a corporate update.“Our recent achievement of several critical milestones exemplifies our focus on execution as we continue the rapid pace of development for our lead program, PB2452,” said Jonathan P. Mow,...

SAN DIEGO, Nov. 14, 2019 (GLOBE NEWSWIRE) — Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the quarter ended September 30, 2019 and provided a company update.“The third quarter was marked by tremendous progress for Daré and positioned us to reach a number of milestones in the fourth quarter of 2019 and into 2020,” said Sabrina Martucci Johnson, President and CEO of Daré. “Earlier this week, we announced positive topline results of the postcoital test pre-pivotal clinical trial of Ovaprene®, our monthly, hormone-free vaginal contraceptive candidate. The data from that study will be used to support an Investigational Device Exemption and, pending FDA review and clearance of the IDE, we plan to initiate a pivotal contraceptive effectiveness and safety study of Ovaprene...

TORONTO, Nov. 14, 2019 (GLOBE NEWSWIRE) — Spectral Medical Inc., (TSX: EDT), a Phase III company developing the first treatment for patients with septic shock guided by a companion diagnostic, today announced its unaudited financial results for the third quarter ended September 30, 2019.Financial ReviewRevenue for the three-months ended September 30, 2019 was $534,000 compared to $579,000 for the same three-month period last year. For the nine-months, ended September 30, 2019, revenue was $2,122,000 compared to $1,976,000 in the first nine months of 2018. The increase is due to the completion of certain performance obligations related to the licensing and technology transfer agreement entered into at the end of 2018. The increase was offset, in part, by a reduction in royalty revenue generated from contracts related to the Company’s...

Third Quarter Highlights – 2019 vs. 2018 Revenue up 22% to $6.2 million from $5.1 millionNet income attributable to WFCF up 43% to $541,000 from $377,000Adjusted EBITDA up 18% to $1.0 million from $867,000Nine-Month Highlights – 2019 vs. 2018Revenue up 14% to $15.1 million from $13.2 millionNet income attributable to WFCF up 29% to $759,000 from $590,000Adjusted EBITDA up 6% to $1.9 million from $1.8 millionCash generated from operations up 44% to $2.3 million from $1.6 millionCASTLE ROCK, Colo., Nov. 14, 2019 (GLOBE NEWSWIRE) — Where Food Comes From, Inc. (WFCF) (OTCQB: WFCF), the most trusted resource for independent, third-party verification of food production practices in North America, today announced its 2019 third quarter and nine-month financial results.“We’re very pleased with our financial performance,” said John Saunders,...